Summit Therapeutics Inc. (NASDAQ: SMMT) Co-Chief Executive Officer Mahkam Zanganeh executed a significant insider purchase, acquiring company common stock valued at $1,460,000 on June 4, 2026. The transaction involved the acquisition of 100,000 shares at a price of $14.60 per share. These shares were obtained indirectly through the Mahkam Zanganeh Revocable Trust, with Ms. Zanganeh serving as the Trustee. This move adds to her existing portfolio, as she also serves as a Director and is identified as a Ten Percent Owner of Summit Therapeutics Inc.
The timing of this acquisition is particularly notable given the current market context. The stock was trading at $14.83 at the time of the report, a level near its 52-week low of $13.83. According to InvestingPro analysis, the stock has declined 14.76% over the past week. The company carries an overall "WEAK" financial health score and remains unprofitable, with an EPS of -$1.59. Following this transaction, Ms. Zanganeh’s indirect holdings through the Mahkam Zanganeh Revocable Trust total 25,824,474 shares. The report also indicates indirect holdings of 76,680 shares by an immediate family member, 570,073,879 shares by her spouse, and 10,199,776 shares through the Shaun Zanganeh Irrevocable Trust, where she is also Trustee. Additionally, Ms. Zanganeh directly holds 31,000 shares of Summit Therapeutics common stock. The reporting person disclaims beneficial ownership of these indirectly held securities, except to the extent of her pecuniary interest therein, if any.
In other recent news, Summit Therapeutics has been the focus of several analyst evaluations following the presentation of trial data. Cantor Fitzgerald has reiterated its Overweight rating on Summit Therapeutics, citing positive data from the Phase 3 HARMONi-6 trial presented at an ASCO plenary session. This trial, conducted in China, evaluated ivonescimab plus chemotherapy against tislelizumab plus chemotherapy in first-line squamous non-small cell lung cancer. The trial reported an overall survival benefit, achieving a 0.66 hazard ratio, which indicates a favorable outcome for patients. Stifel, meanwhile, has reiterated a Buy rating and set a price target of $45.00, highlighting the four-month median overall survival improvement in the HARMONi-6 trial. These perspectives underscore the varied interpretations of the trial data and its implications for Summit Therapeutics.
Conversely, Bernstein SocGen Group has maintained an Underperform rating on Summit Therapeutics, with a price target of $7.70. Bernstein expressed concerns regarding the applicability of the HARMONi-6 trial results to Summit’s global HARMONi-3 Phase 3 trial. These differing analyst perspectives highlight the complex landscape surrounding the company's valuation and future prospects.